Stock Analysis
- Italy
- /
- Life Sciences
- /
- BIT:FF
Fine Foods & Pharmaceuticals N.T.M Reports Third Quarter 2024 Earnings
Fine Foods & Pharmaceuticals N.T.M (BIT:FF) Third Quarter 2024 Results
Key Financial Results
- Revenue: €55.1m (down 5.3% from 3Q 2023).
- Net income: €2.14m (up from €97.1k loss in 3Q 2023).
- Profit margin: 3.9% (up from net loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Fine Foods & Pharmaceuticals N.T.M Earnings Insights
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Italy.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before we wrap up, we've discovered 1 warning sign for Fine Foods & Pharmaceuticals N.T.M that you should be aware of.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About BIT:FF
Fine Foods & Pharmaceuticals N.T.M
Fine Foods & Pharmaceuticals N.T.M. S.p.A.